20 June 2013
Keywords: ipsen/medicis, submit, reloxin, bla, fda, french, drugmaker
Article | 24 March 2008
French drugmaker Ipsen has submitted a Biologics License Application to the US Food and Drug Administration for its esthetic-use botulinum
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 March 2008
19 June 2013
© 2013 thepharmaletter.com